Vaxart Q3 net loss narrows to $14.1M; COVID Phase 2b sentinel enrollment near completion

Vaxart, Inc.

Q3 revenue $4.9M (up from $2.1M YoY) from BARDA contracts; net loss per share $0.06 vs $0.11.
Cash $58.7M; expects runway into 2026; R&D $15.1M, G&A $4.3M.
Sentinel cohort enrollment of Phase 2b COVID vaccine trial expected to complete Nov 2024; 10,000-participant phase could start early 2025 if safety data favorable.
FDA requested new clinical data for norovirus program; Vaxart created more potent GI.1 and GII.4 constructs.
Preclinical data on HPV mucosal vaccine published in Vaccines in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.